Fig. 1: Knockdown of LFPRLR reduces splenic B-cell subsets in SLE-prone mice.

a–c Experimental design (a), verification of LFPRLR knockdown in total splenic WBCs by qPCR (b), and splenic WBC counts (c) in MRL-lpr mice treated with control SMO [n = 9 for (b) and n = 14 for (c), red] or LFPRLR SMO [n = 10 for (b) and n = 14 for (c), blue]. d–f Quantitation and representative flow cytometry plots of CD3⁻CD19⁺ B cells and CD19⁻CD3⁺ T cells (d); CD11c⁺PDCA1⁺ pDCs and CD11c⁺PDCA1⁻ cDCs (e); Blimp1⁺CD138⁺ total plasma cells, Blimp1⁺CD138⁺B220⁺ plasmablasts, and Blimp1⁺CD138⁺B220⁻ long lived plasma cells (f) in spleens of MRL-lpr mice treated with control SMO (n = 14, red) or LFPRLR SMO (n = 12, blue). Graphs show median ± interquartile range. Each dot in qPCR analyses of transcripts corresponds to the mean expression of that gene in one mouse calculated from 3 technical replicates. Ubiquitin B (Ubb) was used as the house-keeping gene in qPCR. Exact p-values were calculated using the Mann–Whitney U test. ns non-significant.